News
OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025
OMS1620 is advancing through IND-enabling studies for diseases associated with ACTH excess, including congenital adrenal ...
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer ...
Research Progress on Ferroptosis Mechanism in Endometrial Cancer. Journal of Biosciences and Medicines, 13, 65-74. doi: 10.4236/jbm.2025.137005 . Endometrial Cancer (EC) is an epithelial malignant ...
The α-factor receptor of the yeast Saccharomyces cerevisiae encoded by the STE2 gene is a member of the large family of G protein-coupled receptors (GPCRs) that mediate multiple signal transduction ...
We conclude that intracellular Ang II binds to intracellular Ang II receptors and elicits an increased [Ca 2+] i in the injected cell and, thereafter, cells in the immediate neighborhood. Cell-cell ...
A breakthrough in the understanding of how mammals create red blood cells could lead to opportunities for artificial blood to ...
OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ...
Adenosine deaminase 2 (ADA2) plays a critical role in immune regulation, particularly in monocyte differentiation and ...
The Semaglutide peptide has emerged as a compelling subject in biochemical and physiological research due to its potential ...
Lung macrophages play a pivotal role in diseases like idiopathic pulmonary fibrosis. Two types of macrophages—the white blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results